Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors-Reference-Cited by-同舟云学术

Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors

Published:2018-04-16 Issue:6 Volume:178 Page:1462-1463
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Horikawa H.¹^ORCID,Kurihara Y.¹,Funakoshi T.¹,Umegaki-Arao N.¹,Takahashi H.¹,Kubo A.¹,Tanikawa A.¹,Kodani N.²³,Minami Y.²,Meguro S.²,Itoh H.²,Izumi K.⁴,Nishie W.⁴,Shimizu H.⁴,Amagai M.¹,Yamagami J.¹

Affiliation:

1. Department of Dermatology; Keio University School of Medicine, Shinjuku-ku; Tokyo Japan

2. Division of Endocrinology, Metabolism, and Nephrology; Department of Internal Medicine; Keio University School of Medicine, Shinjuku-ku; Tokyo Japan

3. Center for Preventative Medicine; Keio University School of Medicine, Shinjuku-ku; Tokyo Japan

4. Department of Dermatology; Hokkaido University Graduate School of Medicine, Kita-ku; Sapporo Japan

Funder

Ministry of Health, Labour and Welfare

Keio Gijuku Academic Development Fund

Publisher

Wiley

Subject

Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjd.16479/fullpdf

Reference6 articles.

1. Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: report of two cases;Pasmatzi;Diabetes Care,2011

2. Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature;Attaway;J Dermatol Case Rep,2014

3. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database;Béné;Br J Dermatol,2016

4. Bullous pemphigoid: end of the century overview;Liu;J Dermatol,2001

5. Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid;Izumi;J Invest Dermatol,2016

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Type 2 Diabetes and its Treatment with Linagliptin are both Associated with Elevated Mortality in Bullous Pemphigoid;Acta Dermato-Venereologica;2024-09-04

3. From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid;International Journal of Molecular Sciences;2023-11-26

4. Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid diagnosed by oral manifestation;Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology;2023-11

5. Biomarkers for predicting immune reconstitution inflammatory syndrome in dipeptidyl peptidase‐4 inhibitor‐associated bullous pemphigoid: A retrospective observational study with a case series;JEADV Clinical Practice;2023-09-11